{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:12:10Z","timestamp":1791396730674,"version":"4.3.3"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Child &amp; Adolescent Psychiatry"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1097\/01.chi.0000145372.61239.bb","type":"journal-article","created":{"date-parts":[[2004,12,16]],"date-time":"2004-12-16T09:02:51Z","timestamp":1103187771000},"page":"73-79","source":"Crossref","is-referenced-by-count":93,"title":["Electrocardiographic Changes in Children and Adolescents Treated With Ziprasidone: A Prospective Study"],"prefix":"10.1016","volume":"44","author":[{"given":"JENNIFER","family":"BLAIR","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LAWRENCE","family":"SCAHILL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MATTHEW","family":"STATE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANDR\u00c9S","family":"MARTIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/01.chi.0000145372.61239.bb_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/hrt.70.1.43","article-title":"QT interval variables from 24 hour electrocardiography and the two year risk of sudden death","volume":"70","author":"Algra","year":"1993","journal-title":"Br Heart J"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib2","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1001\/jama.289.16.2120","article-title":"What clinicians should know about the QT interval","volume":"289","author":"Al-Khatib","year":"2003","journal-title":"JAMA"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib3","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib4","first-page":"570","article-title":"The aberrant behavior checklist: factor structure and the effect of subject variables in American and New Zealand facilities","volume":"91","author":"Aman","year":"1987","journal-title":"Am J Ment Defic"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib5","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1067\/mhj.2002.125804","article-title":"Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management","volume":"144","author":"Anderson","year":"2002","journal-title":"Am Heart J"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib6","author":"Anonymous"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib7","author":"Anonymous"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib8","author":"Anonymous"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-200209000-00001","article-title":"A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg\/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study","volume":"17","author":"Arato","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib10","first-page":"353","article-title":"An analysis of the time-relations of electrocardiograms","volume":"7","author":"Bazett","year":"1918","journal-title":"Heart"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib11","first-page":"1","article-title":"The QT interval","volume":"43","author":"Bednar","year":"2001","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib12","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00702-004-0153-8","article-title":"Electrocardiographic safety profile and monitoring guidelines in pediatric psychopharmacology","volume":"111","author":"Blair","year":"2004","journal-title":"J Neural Transm"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone 80 mg\/day and 160 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group","volume":"20","author":"Daniel","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0009-9236(99)70117-7","article-title":"Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)","volume":"65","author":"Desta","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00004714-200006000-00005","article-title":"Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome","volume":"20","author":"Flockhart","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1176\/ajp.144.5.673","article-title":"ECG changes during haloperidol and pimozide treatment of Tourette's disorder","volume":"144","author":"Fulop","year":"1987","journal-title":"Am J Psychiatry"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib17","doi-asserted-by":"crossref","first-page":"14B","DOI":"10.1016\/0002-9149(93)90034-A","article-title":"How to measure the QT interval-what is normal?","volume":"72","author":"Garson","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib18","author":"Gordon"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib19","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1097\/00004583-199908000-00022","article-title":"AHA scientific statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs","volume":"38","author":"Gutgesell","year":"1999","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib20","series-title":"ECDEU Assessment Manual for Psychopharmacology","article-title":"Clinical Global Impression (CGI)","author":"Guy","year":"1976"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/clpt.1992.135","article-title":"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin","volume":"52","author":"Honig","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib22","series-title":"Epidemiology, Biostatistics, and Preventive Medicine","author":"Jekel","year":"1996"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib23","first-page":"849","article-title":"Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals","volume":"22","author":"Jurima-Romet","year":"1994","journal-title":"Drug Metab Dispos"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1023\/A:1016389227576","article-title":"QT interval measurements","volume":"6","author":"Kautzner","year":"2002","journal-title":"Card Electrophysiol Rev"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00004714-200102000-00007","article-title":"Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies","volume":"21","author":"Keck","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib26","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1176\/appi.ajp.160.4.741","article-title":"Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial","volume":"160","author":"Keck","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib27","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/01.CHI.0000046860.56865.25","article-title":"The relevance of prolonged QTc measurement to pediatric psychopharmacology","volume":"42","author":"Labellarte","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/00004583-198907000-00015","article-title":"The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity","volume":"28","author":"Leckman","year":"1989","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00002018-200124050-00001","article-title":"Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling","volume":"24","author":"Malik","year":"2001","journal-title":"Drug Saf"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib30","unstructured":"Malone RP, Delaney MA, Gifford C (2003), Ziprasidone treatment-associated changes in QTc and weight in adolescents with autism. Poster presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Miami, October"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib31","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00004583-200208000-00010","article-title":"Case series: use of ziprasidone for maladaptive symptoms in youths with autism","volume":"41","author":"McDougle","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1542\/peds.108.1.8","article-title":"Diagnostic accuracy of screening electrocardiograms in long QT syndrome I","volume":"108","author":"Miller","year":"2001","journal-title":"Pediatrics"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib33","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/0002-9149(91)90541-R","article-title":"Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia","volume":"67","author":"Morganroth","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib34","doi-asserted-by":"crossref","first-page":"23B","DOI":"10.1016\/0002-9149(93)90036-C","article-title":"Measurement of the QT interval and the risk associated with QTc interval prolongation: a review","volume":"72","author":"Moss","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib35","first-page":"85","article-title":"Delayed repolarization (QT or QTU prolongation) and malignant ventricular arrhythmias","volume":"51","author":"Moss","year":"1982","journal-title":"Mod Concepts Cardiovasc Dis"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib36","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/00004583-200205000-00003","article-title":"Experience with ziprasidone","volume":"41","author":"Patel","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-200015040-00003","article-title":"Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance","volume":"15","author":"Pezawas","year":"2000","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib38","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMoa022147","article-title":"Risk stratification in the long-QT syndrome","volume":"348","author":"Priori","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib39","first-page":"690","article-title":"Sex differences in the evolution of the electrocardiographic QT interval with age","volume":"8","author":"Rautaharju","year":"1992","journal-title":"Can J Cardiol"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib40","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(00)02035-3","article-title":"QTc-interval abnormalities and psychotropic drug therapy in patients","volume":"355","author":"Reilly","year":"2000","journal-title":"Lancet"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib41","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","article-title":"Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study","volume":"39","author":"Sallee","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib42","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","article-title":"A placebo-controlled trial of risperidone in Tourette syndrome","volume":"60","author":"Scahill","year":"2003","journal-title":"Neurology"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib43","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/104454601317261555","article-title":"Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism","volume":"11","author":"Scahill","year":"2001","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib44","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/00004583-199706000-00023","article-title":"Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity","volume":"36","author":"Scahill","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib45","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-2999(01)01188-8","article-title":"Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile","volume":"425","author":"Schmidt","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib46","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/archpsyc.1989.01810080052006","article-title":"Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome","volume":"46","author":"Shapiro","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib47","first-page":"555","article-title":"Reproducibility of QTc-measurements in healthy volunteers","volume":"48","author":"Vervaet","year":"1993","journal-title":"Acta Cardiol"},{"key":"10.1097\/01.chi.0000145372.61239.bb_bib48","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/00004583-199611000-00018","article-title":"Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents","volume":"35","author":"Wilens","year":"1996","journal-title":"J Am Acad Child Adolesc Psychiatry"}],"container-title":["Journal of the American Academy of Child &amp; Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856709613447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856709613447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T23:03:28Z","timestamp":1682895808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856709613447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0890856709613447"],"URL":"https:\/\/doi.org\/10.1097\/01.chi.0000145372.61239.bb","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}